In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covagen AG

Division of Cilag GmbH International/Covagen AG
www.covagen.com

Latest From Covagen AG

Biopharma Dealmaking Quarterly Statistics, Q3 2014

Biopharma financing dropped 22% in Q3 to $5.65 billion. In the largest M&A, Roche bulked up on rare diseases, gaining Esbriet through its $8 billion takeover of InterMune; Sanofi dominated in alliance dealmaking.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device

Deal Watch: Roche Wins Potential Blockbuster Esbriet In $8.3B Buyout Of InterMune

While Valeant prepares for an October court date to resolve Allergan’s attempt to fend off its latest takeover attempt, the acquisitive Canadian specialty firm picked up some dermatology products from Valeo Pharma. Also this week, Cilag acquired Covagen and Vaccinogen raised $80 million for development of OncoVAX.

BioPharmaceutical Deals

Start-Up Execs On The Move, January 2014

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Cilag GmbH International
  • Johnson & Johnson
  • Senior Management
  • Julian Bertschinger, PhD, CEO
    Dragan Grabulovski, PhD, CSO
    Elias Papatheodorou, CBO
  • Contact Info
  • Covagen AG
    Phone: (49) 44 732 46 60
    Wagistrasse 25
    Zurich-Schlieren, CH-8952
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register